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Human immunodeficiency virus (HIV) Type 1 infection predominantly affects 
the immune system. Nevertheless, scientific studies have proven its association 
with the Central Nervous system (CNS) causing several neurological 
complications leading to HIV Associated Dementia (HAD). HAD is 
characterized by a progressive, disabling decline in essential CNS functions 
such as cognition, motor control and behavior. These are the general 
characteristics of the most common Neuro degenerative diseases such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD). The genetics of AD 
and PD is widely studied and clinical studies have shown cohesion in the 
pathology of HAD, AD and PD. Analysing the concurrent expression patterns 
of large number of genes amongst these related diseases will aid in establishing 
correlations between the genes and their functions. 
We have analysed the gene expression datasets of HAD, AD and PD from GEO 
database to determine the overlapping genes and transcription factors involved. 
The datasets were normalized using R-Bioconductor, and statistical analysis 
was performed to identify the significant genes using limma and related 
packages in R. Although substantial amount of common proteins among HAD 
and other Neuro degenerative diseases have been previously reported, our 
findings can help in expanding the pool of target genes and further enhancing 
the knowledge about the convergent pathways among HAD, AD and PD. These 
common markers identified will provide insights into parallel pathways of 
disease mechanisms and further assist in the understanding of progression of 
HAD pathogenesis. 
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1. INTRODUCTION  
The existence of HIV infection in patients suffering from AIDS induces HIV Associated Dementia (HAD), 
a neurological condition and a common complication of HIV disease. The pre-highly active antiretroviral 
therapy (HAART) era reported the prevalence of HAD at least 20% - 30% in advanced HIV infections [1]. With 
the advent of HAART, incidence of HAD has decreased; however, there is an increase in its prevalence due to 
the prolonged existence of HIV [2]. HAD patients generally suffer from HIV-associated Encephalitis (HIVE) 
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with viral replication limited to cells of monocyte origin [3]. The neuropathology of HIVE includes infiltration 
of central nervous system (CNS) by macrophages, activation of microglial cells, perivascular or parenchymal 
monocytes, multinucleated giant cells, and lymphocytes [4], [5]. Additionally, HIVE and HAD are associated 
with substantial neuronal loss, formation of abnormal dendrites, secretion of chemokines, pro-inflammatory 
cytokines, nitrous oxide, and other neurotoxic factors produced by infected and activated cells leading to 
damaging cellular responses. This is followed by the altered gene expressions of neuronal growth factors, 
cytokines and cell death genes leading to potential impairment of blood–brain barrier permeability, development 
of brain atrophy lastly culminating in brain injury [5 - 7]. Scrupulous investigations of HIV-1 infection carried 
out over the years have identified various factors and genes associated with the pathogenesis of HAD, 
constituting T-cell receptor-mediated signaling, subcellular trafficking, transcriptional regulation, and diverse 
cellular metabolic pathways [8]. Remarkable gene expression profiles have been demonstrated as a result of 
HIV-altered signal transduction of neuronal cells along with alteration in astrocyte function [9]. Diverse range 
of serological markers like tumour necrosis factor alpha, monocyte chemo-attractant protein 1, interleukin-6, 
and high-sensitivity C-reactive and soluble CD14 proteins are recognized to play a role in progression of HAD 
pathogenesis leading to rigorous metabolic alterations [10]. Nevertheless, despite the numerous advances in the 
revelation of the HIV-1 pathophysiology, the molecular mechanisms implicated in HIV associated dementia 
remains poorly understood. 
Gene expression studies have been extensively used to investigate the various cellular mechanisms linked 
to HAD pathogenesis [11]. Ongoing studies dealing with genomic and transcriptomic factors underlying the 
disease have provided significant insights about neuro-pathogenesis associated with HAD and has positively 
driven identification of treatment targets. Gelman et al. in their study revealed two distinct transcriptome 
profiles linking two distinct pathways to HIV associated neurocognitive disorder (HAND). A complete variation 
in the expression was observed in HAND patients with and without HIVE which reflected the up-regulation and 
down-regulation of the inflammatory pathways [12]. Numerous studies have drawn parallels among diverse 
neurodegenerative diseases with respect to pathophysiology of unusual protein assemblies suggesting 
commonalities with HAD development [13]. Studies dealing with identification of amylodoigenic potential of 
HIV-1 proteins has revealed that they have a potential to contribute aggregation [14]. Thus, along with the 
physiologic features, these diseases do share common genetic factors leading to the diseased state. AD is a type 
of dementia which is ranked third by the experts and is a widely studied multifaceted, irreparable, progressive 
brain sickness, which reduces memory and thinking skills in a slow pace [15]. A study on the neurocognitive 
impairment in AD and HIV identified commonly associated genes between them and reported the dysregulation 
of shared mitochondrial gene networks and upregulation of various cancer-related genes [16]. A meta-analysis 
of transcriptomes derived from different regions of brain from individuals with HIVE and AD also presented 
shared up-regulation of several immune response genes and downregulation of synaptic transmission and cell 
signalling genes [17]. Neurodegenerative diseases with diverse etiologies possess a general characteristic feature 
of amyloid fibril deposition in brain tissues linked with neuronal apoptosis and cell death [18], [19]. Thus, 
existence of various commonly affected pathways in these diseases is definitely not astonishing. 
In accordance with this fact, and in the view of expanding the pool of target genes we have analyzed the 
gene expression data from HAD, PD and AD datasets. PD is one of the most studied and the second most 
widespread neurodegenerative disorder of the central nervous system [20]. The analysis involves individual 
assessment of respective datasets as well as a combined analysis to put forth the convergent set of genes that are 
concurrently affected in these three diseases. Normalized gene expression data is subjected to statistical analysis 
for determining the most significantly affected genes and the possible role of few genes is discussed further. The 
prospect of the study is to provide insights into the identification of common disease mechanisms underlying 
HAD and other neurodegenerative diseases. 
 
2. RESEARCH METHOD  
2.1 Gene expression datasets 
The raw gene expression profiling datasets by three individual studies of AD, PD and HAD were 
obtained from Gene Expression Omnibus database, an online and publicly available repository that archives 
microarray, next generation sequencing, and other forms of high- throughput functional genomic data [21]. The 
microarray engineering offers unique chances to obtain molecular signatures of the region of activity of diseased 
cells and patient samples. A microarray is a 2D array on a solid substrate that evaluates large amounts of 
biological samples using high-throughput screening. Using random sampling technique 39 non-demented 
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controls and 43 AD affected samples from the AD dataset series GSE528; 9 control and 16 disease replicate PD 
dataset from series GSE7621 and 18 controlled and 36 affected HAD dataset from series GSE35864 samples 
were used in the current study.  All these experimental data is generated on GPL570 [HG-U133_Plus_2] 
Affymetrix Human Genome U133 Plus 2.0 Array, ensuring uniformity for combined integrated analysis. 
 
 
 
Table 1. Count of differentially expressed genes determined in SAM and T-test analysis 
Dataset SAM T-LIMMA (p value < 0.05) Common 
AD 9682 12806 7205 
PD 426 188 141 
HAD 1044 146 109 
Combined 6087 10838 4796 
 
2.2 Dataset Normalization 
Normalization was done for resolving the systematic errors and bias introduced by the microarray 
experimental platform; thus, correcting hybridization intensity to make decisive analysis [22]. The Robust Multi 
array Average (RMA) method available in Bioconductor’s affy package was applied in this study. RMA process 
includes 3 steps: 1) RMA Background Correction; To distinguish the probe-level signal from background signal 
(optical noise & non-specific binding), 2) RMA Normalization; makes all the arrays to have same quantile 
values, thus removing all the variations incorporated during sample preparation and hybridization and 3) RMA 
Summarization; a robust system for centering, using probe-level background-corrected and quantile normalized 
intensities thus giving summarized expression values [23].  Individual diseased datasets as well as combined 
data sets of our study have been normalized and converted to expression set objects for statistical analysis using 
R software package 
R Version 3.4.1 (https://www.r-project.org/) is a language and environment for statistical computing 
and graphics. R provides a wide variety of statistical (linear and nonlinear modelling, classical statistical tests, 
time-series analysis, classification, clustering) and graphical techniques [24]. 
Bioconductor-3.5 (https://www.bioconductor.org/) is an open source and open development software 
project based on R used for the analysis and comprehension of high-throughput genomic data. Bioconductor is 
based on the R programming language. Major workflows in Bioconductor include pre-processing, quality 
assessment, differential expression, clustering and classification, and gene set enrichment analysis [25]. Our 
study uses affy and its dependent packages to read and normalize data and limma and its dependent packages to 
perform differential expression of genes. 
 
2.3 Statistical Analysis of Differential Expression 
Identification of differentially expressed genes in individual diseased datasets and combined dataset 
was carried out using limma package in Bioconductor [26]. Normalized data is submitted for statistical tests like 
t-test and SAM test. Limma uses moderated t-statistic with shrunken standard deviation for each gene to identify 
gene specific difference between means of expression levels of 2 groups (Control and Affected) [26]. The 
topTable( ) method returns a table ranking the genes according to evidence for differential expression. Genes 
with adjusted p value < 0.05 are identified to be differentially expressed. SAM (Significance Analysis of 
Microarrays) is performed using Web-enabled and Cross-platform SAM via Shiny 
(https://github.com/MikeJSeo/SAM) which is a statistical system for identifying significant genes in a set of 
microarray investigates. The input to SAM is gene expression measurements from the normalized microarray 
datasets, as well as a response variable from each dataset. The response variable may be a grouping like control 
and diseased (either unpaired or paired) samples. SAM computes a statistic for each gene, measuring the 
strength of the relationship between gene expression and the response variable. In SAM delta value of 1.01 is 
used to control the false positives. Web platform lists the significant genes in order of q value. Lesser the q 
value results in more statistically significant results. SAM test was performed for 100 permutations with mean 
difference as 10 and delta value as 1. 
 
2.4 Metabolic engineering analysis 
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Metabolic engineering provides a framework for genome-wide differential gene expression data 
analysis. It combines with data on protein content that further correlates to the pathways involved, thus having 
biotechnological applications for screening candidate drugs or designing gene therapies [27]. Here in we have 
analyzed metabolic engineering pathways of the ITPKB gene in combined dataset using KEGG database [28]. 
 
3. RESULTS AND ANALYSIS  
The normalized expression sets of individual diseases were compared to check for overlapping genes; 
however no overlapping genes were found among the three diseases. Hence, an integrated analysis was 
performed wherein the raw datasets of all three diseases were normalized together to form a combined 
normalized set and then subjected to statistical analysis. 
 
3.1 Box plot analysis 
Box plots are graphical tools to visualize key statistical measures, such as median, mean and quartiles 
[29]. Boxplots for microarray experiments shows distribution of overall gene expression values between arrays. 
Meaningful statistical analysis and inferences from the data can be performed only if the samples are 
comparable. Boxplots helps to visualize the expression across samples by comparing raw and normalized data. 
After normalization, probe intensity values are centred on the median and the range of distribution is reduced by 
eliminating the highly diverse values as outliers. The supplementary file (SF) figures 1 - 3 displays the box plots 
of raw and normalized AD, PD and HAD datasets respectively. SF figures 4 and 5 displays respective box plots 
of raw and normalized data of the combined (all three diseased states) dataset. 
 
3.2 Histogram Analysis 
A histogram is used to graphically summarize and display the distribution of a processed data set. A 
frequency distribution shows how often each different value in a set of data occurs. It is most commonly used to 
show frequency distributions of log2 intensities of perfect match probes for comparison of probe intensity 
behavior between different arrays. Histograms of all the individual datasets have been plotted for visualization 
while histogram for the combined dataset (raw and normalized) is displayed in SF figure 6.  
 
3.3 Visualization of data 
In heat maps, the data is represented in a grid where each row denotes a gene and each column denotes 
a sample. A heat map of normalized expression dataset gives a graphical representation of individual gene 
intensity values with respect to the samples under study in form of a color scheme. It also depicts hierarchical or 
k-means clustering of the samples (normal vs diseased) according to their expression values, so as samples 
expressing similar variations in gene intensities are clustered together forming a tree like structure 
(https://www.ebi.ac.uk/training/online/course/functional-genomics-ii-common-technologies-and-data-analysis-
methods/biological-0). Figure 1 represents the heat map generated from the integrated data for AD, PD and 
HAD datasets reflecting gene expression values in several conditions. 
 
3.4 Statistical Tests 
T test and SAM test listed a significant amount of differentially expressed genes in individual datasets 
of AD, PD and HAD as well as in combined dataset as described in Table 1. The common genes identified from 
SAM and T-test were considered to form a consensus dataset. Table 2 and 3 describes the top 5 upregulated and 
5 downregulated genes from the consensus set of 4796 genes identified after statistical tests. We have also 
derived set of overlapping genes between the consensus genes of Combined Dataset and AD. Total of 5171 
genes were identified to overlap out of which top 5 upregulated and top 5 downregulated genes are described in 
SF table 1 and 2. A total of 72 overlapping genes were identified between the consensus set of combined and 
HAD genes. SF table 3 describes the top 5 genes of this set. No downregulated genes were obtained in this 
combination. A total of 63 overlapping genes were identified between consensus set of combined and PD. SF 
table 4 describes top 5 and SF table 5 describes the top 3 genes of this combination. About 55 overlapping genes 
were derived between the consensus set of HAD and AD as denoted in SF table 6, however no genes were 
identified to overlap between the HAD and PD dataset. SF table 7 describes top 5 genes found to be upregulated 
in HAD but downregulated in AD. The total genes set derived of each combination will be made available in 
excel sheet upon request to the author. 
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ITPKB gene identified to be upregulated in the top 5 differentially expressed genes set of combined 
dataset as shown in table 3 is reported to be involved in enhancing amyloid production by overexpressing in the 
neurons of APP mice. ITPKB is involved in Inositol phosphate metabolism and Calcium signaling pathway. The 
protein Inositol-trisphosphate 3-kinase B is responsible in regulating the levels of several inositol 
polyphosphates that are critical in cellular signaling [30]. Salta et al. in their study have also reported the 
upregulation of ITPKB in human AD patients [31]. Thus, its inclusion in this combined set explains that this 
gene is upregulated in all three conditions AD, PD and HAD. It is also evident from table 10 that it is one of the 
top five differentially expressed genes between HAD and AD. NFASC gene codes for neurofascin protein 
functions in neurite outgrowth, neurite fasciculation, organization of the axons and involved in neural 
development [32]. NFASC has been reported to be a predicted target of hsa-miR-5010-3p in AD [33]. HIPK2 
found to be upregulated in the combined set is reported to be associated with ER-stress-mediated 
neurodegeneration on activation and is a potential biomarker [34]. CFLAR (C-FLIP) can suppress caspase 8 
activation and mediate apoptosis and its activities are seen to be increased in AD [35]. Along with CFLAR, 
PDCD6 is a part of the functional group of genes that represent a cluster of B-cell lymphoma/leukaemia 11B 
(BCL11B) targets and reported to have a relative abundance in frontal cortex samples in the study performed on 
latent HIV infection [36]. BCL11B is an important transcriptional regulator in the brain [37]. PDCD6 was found 
to be overlapping in the top 5 upregulated genes of HAD and AD. One of the common gene seen to be 
upregulated in HAD and AD is LPP coding for lipoma preferred partner that has already been reported to show 
an increase in AD [35]. Most of the genes found in the integrated study have a higher fold change value for 
upregulation than downregulation. Our combined analysis of all three disease datasets has shown that HAD 
shares more differentially expressed genes with AD than with PD. Shapshak et al. in their work on determining 
relationship between AD and HAD with respect to structure, expression and function have reported genes like 
APBB1 APBB2, APBB3, APLP2 which are known biomarkers in AD to be sharing close chromosomal 
locations with genes viz. HSHIN1, LOC391810, HTATIP2 HTATIP that are expressed in HAD condition [38]. 
Few of the standard deviated genes identified in our study are discussed here, however the knowledge base of 
such genes is quite huge and thorough study on each and every gene may give possible prospects of it to serve 
as biomarker for these diseases. 
 
Figure 1: Heat map generated from the integrated data for AD, PD and HAD datasets reflecting gene expression 
values in several conditions. 
 
Table 2. Top 5 upregulated common (SAM and T-test) genes from combined dataset 
Gene Symbol Description T-Statistics P-value SAM Score Log Fold Change 
PTAR1 Protein prenyltransferase alpha subunit 
repeat containing 1 [Homo sapiens 8.55 1.52E-10 7.047 1.827 
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(human)] 
ITPKB Inositol-trisphosphate 3-kinase B [Homo 
sapiens (human)] 8.256 6.24E-10 7.209 2.541 
NFASC Neurofascin [Homo sapiens (human)] 8.231 6.24E-10 7.028 1.972 
HIPK2 Homeodomain interacting protein kinase 2 [Homo sapiens (human)] 7.823 3.06E-09 6.88 2.252 
CFLAR CASP8 and FADD like apoptosis regulator [Homo sapiens (human)] 7.728074 4.73E-09 6.781 2.384 
Table 3. Top 5 downregulated common (SAM and T-test) genes from combined dataset 
Gene Symbol Description T-Statistics P-value SAM Score 
Log Fold 
Change 
PCYOX1L Prenylcysteine oxidase 1 like [Homo sapiens (human)] -7.96396 1.67E-09 -6.483 0.559 
LGALS8 Galectin 8 [Homo sapiens (human)] -7.43614 1.36E-08 -6.150 0.56 
RIIAD1 
Regulatory subunit of type II PKA R-subunit 
(RIIa) domain containing 1 [Homo sapiens 
(human)] 
-7.41312 1.39E-08 -5.983 0.6514 
FAR2 Fatty acyl-CoA reductase 2 [Homo sapiens (human)] -6.85978 1.13E-07 -5.779 0.5311 
ASAH2B N-acylsphingosine amidohydrolase 2B [Homo 
sapiens (human)] -6.74849 1.69E-07 -5.741 0.4979 
 
 
4. CONCLUSION 
Despite the differences in the mechanisms of AD, PD and HAD, the integrated analysis of these diseases 
has revealed the overlap of differentially expressed genes in this condition. Analysis of HAD and AD datasets 
have presented a potential gene pool of commonly affected genes, while genes shared by HAD and PD did not 
appear in the differentially expressed category. However, a combined integrated analysis did put forth few genes 
possibly affected in neurodegenerative conditions caused by viral as well as non-viral counterparts. 
Identification of biomarkers may assist researchers and clinicians in forecasting the onset of the disease 
progression and in determining the effects of new therapies. A meta- analysis approach allows us to have an 
overall assessment of the gene expressions of the genes involved in various diseases and integrated analysis may 
aid to present genes shared by similar diseases.  
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